No Data
Eli Lilly and Co.'s targeted therapy Retevmo significantly reduced the risk of lung cancer recurrence in late-stage clinical trials.
Eli Lilly and Co stated that its targeted anticancer drug Retevmo significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer.
Eli Lilly Signs Up to $1.26 Billion Deal for Hanmi Pharm's Experimental GLP-2 Drug
Lilly, Haisco Announce Tie-Up That May Be Worth Over $3 Billion
Haisco Announces Licensing and Research Collaboration Agreement With Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)